Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that intravenous administration of a shark-derived receptor antibody, 3P17, promoted hair growth in mice by increasing hair matrix cell proliferation and activating leptin-STAT3 signaling, with transdermal leptin delivery enhancing this effect through improved skin penetration.

In this study, researchers found that minoxidil sulfate enhances the anti-inflammatory effects of the JAK inhibitor baricitinib in alopecia areata, modulating inflammatory signals and preserving immune privilege features in human hair cells, which suggests potential benefits for combined therapy.

In this study, exosomes from hypoxia-conditioned mesenchymal stem cells significantly improved SOCS3 and STAT3 expression in a mouse model of androgenetic alopecia, suggesting they may offer a more effective therapeutic approach than minoxidil by restoring follicular homeostasis.

In this study using a mouse model with alopecia areata, the researchers found that ruxolitinib enhances hair regrowth by inhibiting the JAK-STAT signaling pathway, reducing inflammation and oxidative stress, and decreasing apoptosis, which supports its clinical effectiveness in treating this condition.

This study reports that a new ROS-responsive hydrogel platform delivering miR-665 effectively reduced inflammation and promoted hair follicle regeneration in AA, suggesting a promising treatment approach.

In this study, researchers developed a biocompatible, ROS-responsive hydrogel to deliver miR-665 locally, effectively reducing inflammatory signaling and promoting hair follicle regeneration in an alopecia areata mouse model, offering a promising approach for targeted treatment.

This study found that a newly developed biocompatible hydrogel, responsive to reactive oxygen species, enabled targeted delivery of miR-665, significantly promoting hair regeneration and reducing T-cell infiltration in a mouse model of alopecia areata, suggesting a promising strategy for treating this condition.

In this study, the researchers using Shh-GFP^+/- mice found that cyclophosphamide-induced alopecia involves the JAK/STAT1 pathway, where STAT1 binds the Shh gene promoter, decreasing Shh-expressing cells in hair follicles. Treatment with JAK inhibitors helped rescue hair loss, implicating the JAK/STAT1 pathway in this process.

This study found that miRNA-24 downregulates the KLF6 gene, influencing coat color by affecting melanogenesis pathways in Cashmere goats, and that miRNA-24 inhibition increased melanin content in mice.

This article reviews the current FDA-approved treatments for severe pediatric alopecia areata, including the use of Janus kinase inhibitors, but reports no new clinical findings.

This study found that Enz_MoriL, a compound derived from Morus alba L., promotes hair follicle cell proliferation by affecting the Wnt/β-catenin pathway and can counteract an alopecia areata-like condition by suppressing the JAK-STAT signaling in human hair follicle dermal papilla cells.

This study found that in mice, hyper-activated JAK-STAT1 signaling due to EGFR inhibitor treatment leads to scarring alopecia, but JAK1/2 inhibition can restore hair follicle immune privilege and promote new hair growth.

This study demonstrated that disrupting EGFR signaling in mice leads to immune sensitivity compromising the hair follicle's protective environment, but JAK1/2 inhibition can restore this immune privilege and stimulate hair growth, suggesting a potential therapy for scarring hair loss diseases like cicatricial alopecia.

This observational study in Bogotá found that skin issues like acne and androgenetic alopecia are common among adults with gender dysphoria on hormone therapy, emphasizing the need for dermatological care as part of comprehensive treatment.

This study found that HPV8-induced actinic keratoses may mechanistically involve Lrig1+ hair follicle keratinocyte stem cells, with the E6 gene promoting downstream STAT3 activity in a mouse model.

This study suggests that particulate matter can induce inflammation in human outer root sheath cells, potentially affecting hair growth, through oxidative stress-dependent MAPK and JAK-STAT signaling pathways.

This study found that STAT3 directly inhibits the sheep FST gene and cell proliferation, shedding light on the molecular mechanisms of hair follicle development and wool characteristics.

This study found that elevated STAT5 levels are linked to improved hair-inducing capabilities in human dermal papilla cells, and reducing STAT5 impairs hair follicle induction.

This study identified a specific subset of macrophages as a key source of oncostatin M, maintaining hair follicle stem cell quiescence during the resting phase in mice, suggesting a potential target for treating hair disorders.

This study found that knocking out STAT5 expression in specific mouse hair follicles after tamoxifen treatment initiated uniform hair growth, highlighting STAT5's role in regulating the hair growth cycle.

Oenocarpus bataua vegetable oil may help reduce hair loss by affecting a key gene pathway.

This study found that Stat3 influences the differentiation and migration of keratinocytes, potentially impacting epithelial carcinogenesis, by examining Stat3 activation or deletion effects in mouse models.

This study found that Stat3 deletion in certain skin cells led to increased differentiation and altered stem cell behavior, suggesting its significant role in skin tumor development and keratinocyte migration.

In this study, Stat3 activation in transgenic mice led to a decrease in stem cells in the hair follicle bulge, suggesting its crucial role in epidermal growth and stem cell maintenance.

This review discusses the composition, activation, and regulation of the JAK/STAT pathway and highlights its role and inhibitors in various diseases, but reports no new experimental results.

This review found that JAK/STAT pathway inhibitors, such as tofacitinib and ruxolitinib, led to symptom improvement in all observed atopic dermatitis cases, but responses were mixed for vitiligo and alopecia areata, with a generally mild safety profile reported.

This study reported that inhibiting the JAK-STAT pathway with baricitinib restored cellular homeostasis, delayed senescence, and reduced proinflammatory markers in Hutchinson-Gilford progeria syndrome cell models.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review discusses the potential of drugs targeting the JAK/STAT pathway for dermatological diseases and outlines a protocol to assess existing evidence, reporting no new clinical results.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.